

BAKER BOTTS LLP.Atty. Docket No. 31920-PCT-USA (072900.0107)
PATENT**CLAIM AMENDMENTS**

Please amend the claims as follows:

1-8. (Cancelled).

2 ~~9~~. (Currently amended): The method of claim 7 ¹~~21~~ wherein the human α -interferon is obtained from a lymphoblastoid cell culture.

10. (Cancelled).

3 ~~11~~. (Currently amended): The method of claim 7 ¹~~21~~ wherein the human α -interferon is obtained from lymphocyte cells.

12. (Cancelled).

4 ~~12~~. (Currently amended): The method of claim 7 ¹~~21~~ wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

14. (Cancelled).

5 ~~13~~. (Original): The method of claim ²~~9~~ wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

16. (Cancelled).

6 ~~14~~. (Original): The method of claim ³~~11~~ wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

18-20. (Cancelled).

1 ~~21~~. (Currently amended): A method of treating a subject human having type C viral hepatitis comprising administering to the subject human a daily dose of a liquid ^{formulation}

NY02:479369.1

BAKER BOTTS LLP.Atty. Docket No. 31920-PCT-USA (072900.0107)
PATENT

of human α -interferon, wherein the daily dose is administered by a peroral route, and
wherein the daily dose is between 100 and 500 IU.

NY02:479369.1

3